Isavuconazonium (CAS 241479-67-4) is a high-purity, pharmaceutical-grade antifungal prodrug synthesized via advanced chiral resolution technology, fully complying with USP and EP quality standards. Its molecular structure is optimized to rapidly convert into the active antifungal metabolite isavuconazole in vivo, ensuring enhanced bioavailability and broad-spectrum antifungal activity. Produced with strict impurity control (total impurities ≤0.1%) and zero heavy metal residues, each batch undergoes rigorous potency testing, making it a reliable raw material for systemic antifungal drug formulation.
This triazole-class antifungal prodrug exhibits potent inhibitory effects against a wide range of pathogenic fungi, including Aspergillus and Candida species, which are responsible for severe invasive fungal infections. Unlike traditional antifungal agents, it features a favorable safety profile with minimal liver toxicity, reducing the risk of adverse reactions in long-term clinical use. Its stable chemical properties also support flexible formulation into oral capsules and intravenous injections, catering to diverse clinical treatment needs.
Isavuconazonium (CAS 241479-67-4) caters to professional users such as pharmaceutical manufacturers developing systemic antifungal medications and research institutions exploring antifungal drug mechanisms. Its broad-spectrum efficacy, pharmaceutical-grade purity, and proven safety profile make it a top choice for buyers prioritizing quality and therapeutic performance. Whether for large-scale commercial production or preclinical research, this antifungal prodrug meets the stringent requirements of the global pharmaceutical industry.
